However, theyre not appropriate for pregnant or breastfeeding women, women trying to become pregnant, and people with a history of pancreatitis, certain cancers, some gastrointestinal conditions, or certain kidney diseases
Similar content being viewed by others Introduction Amid the continuously increasing global incidence of diabetes, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a cornerstone in type 2 diabetes treatment, demonstrating remarkable efficacy in glycemic control and cardiovascular risk reduction [1, 2]
Add honey or lemon if desired for taste
Continued Treatment Requirements Current evidence suggests that continued Retatrutide treatment is necessary to maintain weight loss
There is large inter-person variability in response to GLP1 medications both in terms of weight loss and side effects, with the two potentially being related (that is, people who experience more nausea may lose more weight 30 )
This study aims to enhance understanding of the neurological safety profile of GLP-1 RAs and inform clinical practice and patient care
